amplification was seen with primers for the human γ-interferon gene (8) or the human growth hormone gene, indicating the specificity of this inhibition. Several reaction parameters were evaluated for their influence on discrimination between mutant and wt Ki-ras alleles, e.g. the T m of the competing generic primer, PCR temperature profiles, the total number of cycles, buffer composition and different polymerases. Among these, the total number of PCR cycles, the oligonucleotide annealing temperature and the amount of template DNA added were most important. A significant improvement was achieved by addition of glycerol (7.5% v/v) to the reaction. After optimization the assay was able to detect all tested Ki-ras mutations irrespective of the site or type of the mutation in a single PCR (Fig. 2) . A 429 bp fragment of the human growth hormone gene was coamplified in each reaction to exclude unspecific PCR inhibition in cases with no Ki-ras amplification. We also checked the sensitivity of our method by diluting a sample carrying a heterozygous GGT!GAT mutation in codon 12 in wt DNA. Under the conditions described, the mutation was detected down to one mutant allele in a background of 200 wt alleles. Direct sequencing confirmed that the mutant allele was amplified predominantly ( Fig. 3D) , whereas sequence analysis of the same sample reacted without PNA failed to detect the alteration (Fig. 3C ).
* To whom correspondence should be addressed Figure 2 . Detection of different Ki-ras mutations in codons 12 and 13 using PNA mediated PCR clamping. The 157 bp Ki-ras product in lanes 2-7 indicates the presence of a mutation in the corresponding tumor, whereas wt-controls (lanes 8-10, lower band) are negative for Ki-ras, even with a 3-fold excess of DNA (0.45 µg) added (lane 10). Coamplification of a 429 bp fragment of the human growth hormone gene (HGH) was done in each reaction to exclude unspecific inhibition in negative cases (lanes 2-10, upper band). PCR was performed in 50 µl, containing 100 µM deoxynucleoside-triphosphates, 0.001% gelatine, 50 mM KCl, 1.5 mM MgCl 2 and 10 mM Tris-HCl (pH 8.3), 0.25 µM KRAS-1 (5′-GTACTGGTGGAGTATTTGATAGTG-3′) and KRAS-2 (5′-AT-CGTCAAGGCACTCTTGCCTAC-3′) primers, 0.12 µM HGH-s (5′-GCCT-TCCCAACCATTCCCTTA-3′) and HGH-as (5′-TCACGGATTTCTGTTGT-GTTTC-3′) primers, 2.84 µM PNA-1 (H 2 N-TACGCCACCAGCTCC-CON 2 H; Perseptive Biosystems, Freiburg, Germany), 7.5% glycerol (v/v) and 0.15 µg template DNA. The mixture was covered with 50 µl paraffin oil. To prevent unspecific polymerization prior to thermal cycling, hot start was performed by adding Taq polymerase (1 U; Perkin Elmer Cetus) after 5 min incubation at 94_C. PCR consisted of 28 cycles with 94_C/60 s, 70_C/50 s, 58_C/50 s and 72_C/60 s, with 180 s at 94_C in the first cycle and an additional final extension cycle with 94_C/1 min and 60_C/10 min. The additional 70_C step was performed in order to achieve preferential annealing of the PNA. Ten microliters of the reaction were electrophoresed on a 3% agarose-gel and stained with ethidium bromide (0.5 µg/ml).
In our eyes the major advantage of PNA mediated PCR clamping over published assays seems to be the higher flexibility which allows detection of mutations stretched over 4-6 bp in a single reaction. In addition, this method is not restricted to specific base exchanges, a major drawback of procedures using allele specific amplification (9). In conclusion, PNA-mediated PCR clamping is an attractive tool for the detection of ras gene point mutations. The simplicity and versatility make it especially helpful in large scale screening programs. Due to the special situation, ras gene mutations are ideally suited targets, but the assay could also be a rapid and sensitive prescreening method for common clustering mutations in other genes, such as hot-spot mutations in codons 175, 248 or 273 of the p53 tumor suppressor gene. 
